WuXi inks $1.5B GSK pact, a big biobuck bet but a blip in billions lost from US unverified list
GSK is tapping into WuXi Biologics’ T cell-engaging antibodies in a deal worth as much as $1.5 billion, as the UK drugmaker looks to follow suit of others in the T cell-engager field, which includes Amgen’s marketed cancer drug Blincyto.
Only $40 million of the GSK deal will initially go to the Shanghai-based contract research and manufacturing giant, but with a biobuck bet above $1 billion, the Big Pharma sees lots of potential. The pact is a boon to WuXi, which suffered a loss of billions in market value after being placed on the US Department of Commerce’s unverified list last February. WuXi was removed from the list last month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
